Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma

Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy. Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in sarcomas. By using established and patient-derived sarcoma cells with...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Martile, Marta, Desideri, Marianna, Tupone, Maria Grazia, Buglioni, Simonetta, Antoniani, Barbara, Mastroiorio, Carlotta, Falcioni, Rita, Ferraresi, Virginia, Baldini, Nicola, Biagini, Roberto, Milella, Michele, Trisciuoglio, Daniela, Del Bufalo, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833676/
https://www.ncbi.nlm.nih.gov/pubmed/29472530
http://dx.doi.org/10.1038/s41389-018-0026-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833676/
https://www.ncbi.nlm.nih.gov/pubmed/29472530
http://dx.doi.org/10.1038/s41389-018-0026-x

Ejemplares similares